Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In cases of severe deficiency, a course of injections may be given over several weeks before transitioning to maintenance treatment
Subjects with obesity: significantly higher NNMT activity in adipose tissue and liver
Tailored Approach to Onset Time Onset varies based on deficiency severity, dosage, and individual health, ensuring a customized treatment plan
AOD 9604 is a fragment of human growth hormone studied for its effect on fat metabolism, with a real but modest evidence base and an important regulatory caveat: it is not an FDA-approved weight loss drug
It works by inhibiting the NNMT enzymea known contributor to fat storage and metabolic slowdown
Safety in Context: Study Limitations While the clinical trial safety data for AOD-9604 is extensive and reassuring, understanding the limitations of this evidence base is essential for balanced interpretation
US$ 24.79
US$ 23.57
US$ 21.45
